Genome Wide Association Studies in Small-Cell Lung Cancer. A Systematic Review.
ASCL1
CHRNA5/A3/B4
Lung neoplasm
Oncogenes
Small-cell lung carcinoma
Journal
Clinical lung cancer
ISSN: 1938-0690
Titre abrégé: Clin Lung Cancer
Pays: United States
ID NLM: 100893225
Informations de publication
Date de publication:
12 Oct 2023
12 Oct 2023
Historique:
received:
12
05
2023
revised:
28
08
2023
accepted:
09
10
2023
medline:
9
11
2023
pubmed:
9
11
2023
entrez:
8
11
2023
Statut:
aheadofprint
Résumé
Small cell lung cancer (SCLC) is one of the deadliest forms of lung cancer, but few information exists regarding the role of genetics, particularly on Genome Wide Association Studies (GWAS). The aim of the study is to explore the evidence available obtained through GWAS studies for SCLC using a systematic review. We performed a literature search in the main databases until July 31st, 2023. We included all human based studies on GWAS for lung cancer which presented results for SCLC. Only studies with participants diagnosed of SCLC with anatomopathological confirmation were included. Fourteen studies were identified; 8 studies showed a relationship between ASCL1 overexpression and SCLC, which may regulate CHRNA5/A3/B4 cluster, producing a consequent nAChR overexpression. Nine papers, including 8 of the previous, found a positive association between SNPs located in chromosome 15 and SCLC. The most important cluster of genes found is CHRNA5/A3/B4 but the mechanism for the role of these genes is unclear. Kyoto Encyclopaedia of Genes and Genome (KEGG) shows that these receptors were found to be overexpressed where nicotine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and N'-Nitrosonornicotine (NNN) acts, involving different routes in SCLC carcinogenesis.
Identifiants
pubmed: 37940411
pii: S1525-7304(23)00195-X
doi: 10.1016/j.cllc.2023.10.002
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure Karl Kelsey is a founder and scientific advisor to Cellintec, which had no role in this research. The other authors declare not to have any conflict of interest.